Abstract
Three hundred and seventy-two patients were randomized between 3 regimens of chemotherapy: cyclophosphamide, intermittent melphalan, and melphalan with prednisone, and were followed up to death or for at least 5 years. There was no difference in survival between the treatments, either overall or in any subgroup of patients. Therefore, the choice among these 3 treatments should be guided by the patient's comfort and convenience. The most important prognostic feature at presentation was the quality of renal function. It was possible to define good, intermediate and poor renal-function groups which were highly correlated with prognosis (X2 for trend = 62.6). The haemoglobin level at presentation was strongly correlated with prognosis among patients in the good renal-function group. Among 107 patients who presented with good renal function and with haemoglobin above 100 g/l, the 5-year survival was 43%. Other prognostic features were much less important when account was taken of renal function and haemoglobin level.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alexanian R., Haut A., Khan A. U., Lane M., McKelvey E. M., Migliore P. J., Stuckey W. J., Jr, Wilson H. E. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969 Jun 2;208(9):1680–1685. doi: 10.1001/jama.208.9.1680. [DOI] [PubMed] [Google Scholar]
- Bergsagel D. E., Griffith K. M., Haut A., Stuckey W. J., Jr The treatment of plasma cell myeloma. Adv Cancer Res. 1967;10:311–359. doi: 10.1016/s0065-230x(08)60081-0. [DOI] [PubMed] [Google Scholar]
- DE BERGSAGEL D. E., MIGLIORE P. J., GRIFFITH K. M. MYELOMA PROTEINS AND THE CLINICAL RESPONSE TO MELPHALAN THERAPY. Science. 1965 Apr 16;148(3668):376–377. doi: 10.1126/science.148.3668.376. [DOI] [PubMed] [Google Scholar]
- Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
- Hobbs J. R. Immunochemical classes of myelomatosis. Including data from a therapeutic trial conducted by a Medical Research Council working party. Br J Haematol. 1969 Jun;16(6):599–606. doi: 10.1111/j.1365-2141.1969.tb00440.x. [DOI] [PubMed] [Google Scholar]
- Hobbs J. R. Paraproteins, benign or malignant? Br Med J. 1967 Sep 16;3(5567):699–704. doi: 10.1136/bmj.3.5567.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]